Gyre Therapeutics (GYRE) Misses Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts GYRE Hot Sheet
Join SI Premium – FREE
Gyre Therapeutics (NASDAQ: GYRE) reported Q2 EPS of $0.00, $0.02 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $26.8 million versus the consensus estimate of $28.7 million.
For earnings history and earnings-related data on Gyre Therapeutics (GYRE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
